JAMP-ASA 81MG EC TABLET (ENTERIC-COATED)

País: Canadà

Idioma: anglès

Font: Health Canada

Compra'l ara

Descargar Fitxa tècnica (SPC)
01-09-2022

ingredients actius:

ACETYLSALICYLIC ACID

Disponible des:

VITA HEALTH PRODUCTS INC

Codi ATC:

B01AC06

Designació comuna internacional (DCI):

ACETYLSALICYLIC ACID

Dosis:

81MG

formulario farmacéutico:

TABLET (ENTERIC-COATED)

Composición:

ACETYLSALICYLIC ACID 81MG

Vía de administración:

ORAL

Unidades en paquete:

1000

tipo de receta:

OTC

Área terapéutica:

SALICYLATES

Resumen del producto:

Active ingredient group (AIG) number: 0101169013; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2014-07-30

Fitxa tècnica

                                Jamp - ASA 81 mg EC Page 1 of 46
PRODUCT MONOGRAPH
JAMP - ASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg,
MB
Canada R2J 3W2
Control Number: 264031
Date of Preparation:
February 3, 2011
Date of Revision :
September 1, 2022
Jamp - ASA 81 mg EC Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
........................................................................................................
7
DRUG INTERACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE.....................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
....................................................................11
STORAGE AND STABILITY
...............................................................................................13
DOSAGE FORMS, COMPOSITION AND
PACKAGING......................................................13
PART II: SCIENTIFIC INFORMATION
.........................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................14
CLINICAL
TRIALS................................................................
                                
                                Llegiu el document complet
                                
                            

Documents en altres idiomes

Fitxa tècnica Fitxa tècnica francès 01-09-2022

Cerqueu alertes relacionades amb aquest producte